Abstract: Disclosed in certain embodiments are ZSM-5 zeolite microspheres. The ZSM-5 zeolite microspheres may contain substantially no clay or calcined clay material. The ZSM-5 zeolite microspheres may have a ZSM-5 zeolite content of at least 70 wt. %. Disclosed in certain embodiments is a method of forming ZSM-5 zeolite microspheres including treating microspheres with at least one alkali solution.

Abstract: Disclosed in certain embodiments are ZSM-5 zeolite microspheres. Disclosed in certain embodiments is a method of forming ZSM-5 zeolite microspheres including: 1) shaping a mixture into microspheres where the mixture includes a silica material and of particulates selected from at least one high-density material with an absolute bulk density of at least 0.3 g/cc, ZSM-5 zeolite crystals, and combinations thereof; 2) calcining the microspheres; and 3) reacting and subsequently heating the microspheres with at least one alkali solution to form ZSM-5 zeolite in-situ on the microspheres, where the ZSM-5 zeolite microspheres contain substantially no clay or calcined clay material.

Abstract: Disclosed in certain embodiments are ZSM-5 zeolite microspheres. Disclosed in certain embodiments is a method of forming ZSM-5 zeolite microspheres including: 1) shaping a mixture into microspheres where the mixture includes a silica material and of particulates selected from at least one high-density material with an absolute bulk density of at least 0.3 g/cc, ZSM-5 zeolite crystals, and combinations thereof; 2) calcining the microspheres; and 3) reacting and subsequently heating the microspheres with at least one alkali solution to form ZSM-5 zeolite in-situ on the microspheres, where the ZSM-5 zeolite microspheres contain substantially no clay or calcined clay material.

Abstract: Disclosed in certain embodiments are ZSM-5 zeolite microspheres. Disclosed in certain embodiments is a method of forming ZSM-5 zeolite microspheres including: 1) shaping a mixture into microspheres where the mixture includes a silica material and of particulates selected from at least one high-density material with an absolute bulk density of at least 0.3 g/cc, ZSM-5 zeolite crystals, and combinations thereof; 2) calcining the microspheres; and 3) reacting and subsequently heating the microspheres with at least one alkali solution to form ZSM-5 zeolite in-situ on the microspheres, where the ZSM-5 zeolite microspheres contain substantially no clay or calcined clay material.

Abstract: Disclosed in certain embodiments are ZSM-5 zeolite microspheres. Disclosed in certain embodiments is a method of forming ZSM-5 zeolite microspheres including: 1) shaping a mixture into microspheres where the mixture includes a silica material and of particulates selected from at least one high-density material with an absolute bulk density of at least 0.3 g/cc, ZSM-5 zeolite crystals, and combinations thereof; 2) calcining the microspheres; and 3) reacting and subsequently heating the microspheres with at least one alkali solution to form ZSM-5 zeolite in-situ on the microspheres, where the ZSM-5 zeolite microspheres contain substantially no clay or calcined clay material.

Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same. TAT113 polypeptides comprising the amino acid sequence of SEQ ID NO: 2 are disclosed. Antibodies that bind TAT113 polypeptides, including monoclonal, chimeric, humanized, single chain, and other antibodies, and fragments thereof, are disclosed. Methods of identifying antibodies that bind epitopes bound by such antibodies, including the antibodies produced by hybridoma cell lines disclosed in the application, are provided, wherein the ability of one antibody to block the binding of another antibody to a TAT113 polypeptide indicates that one antibody binds to an epitope bound by the other antibody.

Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.

Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.

Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.

Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.

Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.

Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.

Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.

Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.

Abstract: The invention contemplates improved means of control for a copy holder, for example, a roll-operated positioning device for a data draft or the like sheet to be copied by a typist, so that the eye can be guided correctly on a line-by-line basis. The improved control provides precise electric-motor drive for each of a plurality of selected different paper-displacing increments, at least one of the increments being selectively adjustable to exactly match the line spacing unique to the particular paper from which the copy is to be made.